Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus
about
Hydroxychloroquine-related retinal toxicityDeterminants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus.Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug.Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression.Treatment adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and systemic lupus erythematosus.Cigarette smoking and response to antimalarials in cutaneous lupus erythematosus patients: evolution of a dogma.Adherence to Oral and Topical Medications in Cutaneous Lupus Erythematosus is not Well Characterized.Therapy of lupus nephritis: lessons learned from clinical research and daily care of patients.Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence.Improving treatment adherence in patients with rheumatoid arthritis: what are the options?Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers.Electronic monitoring of oral therapies in ethnically diverse and economically disadvantaged patients with rheumatoid arthritis: consequences of low adherenceProlonged improvement of childhood onset systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide.The role of antimalarial agents in the treatment of SLE and lupus nephritis.Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus.New insights into mechanisms of therapeutic effects of antimalarial agents in SLE.Optimizing the use of existing therapies in lupus.Lupus nephritis flare in young patients: relapse or nonadherence to treatment?Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus.Development and validation of a clinical HPLC method for the quantification of hydroxychloroquine and its metabolites in whole blood.Clinical and financial burden of active lupus in Greece: a nationwide study.Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus.Quality of life in systemic lupus erythematosus: description in a cohort of French patients and association with blood hydroxychloroquine levels.Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis.Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).Urine Monocyte Chemoattractant Protein-1 and Lupus Nephritis Disease Activity: Preliminary Report of a Prospective Longitudinal StudyRelationship between blood hydroxychloroquine and desethylchloroquine concentrations and cigarette smoking in treated patients with connective tissue diseasesMeasuring therapeutic adherence in systemic lupus erythematosus with electronic monitoring.Compliance and persistence with hydroxychloroquine in South Korean patients with systemic lupus erythematosus.Health status and concomitant prescription of immunosuppressants are risk factors for hydroxychloroquine non-adherence in systemic lupus patients with prolonged inactive disease.A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires.Hydroxychloroquine desensitization, an effective method to overcome hypersensitivity-a multicenter experience.
P2860
Q26782822-F6DFCAA6-D992-473B-9A06-2E8ED460D645Q33422958-FE4F0A47-1B1C-406A-9E3D-7DF3AC037970Q33747286-A9F6C7FC-3346-4E11-903C-C41287EE17D9Q34003992-A805B3B7-CC80-45F2-96D9-A07FAA2768F2Q34021798-A188C413-F34F-494E-99C9-C022618E673AQ35686749-B5224512-41C7-4D41-A2FB-34CBDE42D720Q35752523-C96DA667-E1BD-4675-9C31-6706134F384FQ36084894-B95766E9-63C0-44D8-8048-8E3752B328F2Q36240425-6B44CA73-6900-447E-9B32-8EC984B3DFBEQ36784125-570AAB46-4646-4FCB-84DA-B9433F26E329Q36843689-D8923E61-A7AE-48BD-80ED-50375E204938Q36950780-A566D20D-B8B8-4DFE-B764-83F826BD1211Q37497048-14614707-B83A-4B44-AC1C-D0478EF4FD6BQ37947108-E44AF5CA-3153-430A-87FF-61F44020563DQ38009852-241FA088-30B8-4EE4-A1BE-7D4E568C9D16Q38026787-E9437FE6-E26E-48BC-A4EF-4EBAB1442B33Q38425824-08CF973F-D3F6-409E-9070-B60A40343211Q38605850-8805402B-4AC3-42B5-A77A-088B25B6188EQ38634472-95207171-FECD-4760-859A-97D07E03590FQ38776952-FDE0F1F0-A837-46FC-8F4F-4EB0F1AF7994Q38800989-EE4D2E95-3332-41DF-B300-A1C78FB8B67EQ38897055-A5A97088-BB03-4079-92F9-BA0E87CACACDQ39997361-71C01CF7-F2A5-4FC1-B8BB-7FC6279F3020Q41915986-6BA916CE-949F-499B-AAE5-2D7C98B34FB1Q41927831-70C5F4EB-D938-4C25-B736-09470496E910Q42390564-CCEC4647-3E8E-4500-AD81-D16EF44273EBQ42753835-F6B4B1D1-7AB9-44AB-818E-046FEB9743D0Q46073827-84CC2CCE-6443-4A41-9D7D-26413ADCBC0AQ47441501-14A27643-8C99-4C3A-949F-1B17E3D4ACAFQ47842487-97B5D6F2-EB92-40AE-913D-6BED96D4EA25Q48588705-DC9B303F-EA70-412D-8362-5A74BF670BF0Q49383523-D64167A8-6B1A-4C22-BD8B-5E2282698F95
P2860
Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Very low blood hydroxychloroqu ...... f systemic lupus erythematosus
@ast
Very low blood hydroxychloroqu ...... f systemic lupus erythematosus
@en
type
label
Very low blood hydroxychloroqu ...... f systemic lupus erythematosus
@ast
Very low blood hydroxychloroqu ...... f systemic lupus erythematosus
@en
prefLabel
Very low blood hydroxychloroqu ...... f systemic lupus erythematosus
@ast
Very low blood hydroxychloroqu ...... f systemic lupus erythematosus
@en
P2093
P2860
P50
P356
P1476
Very low blood hydroxychloroqu ...... f systemic lupus erythematosus
@en
P2093
Donata Marra
Gaëlle Leroux
Guy Aymard
Jean-Sébastien Hulot
Philippe Lechat
P2860
P304
P356
10.1136/ARD.2006.067835
P407
P577
2007-02-26T00:00:00Z